Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

I am still holding only wish I could afford more, thanks for the info GF.

March, UK-based, BioProgress has executed an exclusive licensing agreement for its Xgel Tabwrap dosage form technology with a US pharmaceutical company which is a global leader in the OTC medicines and Nutritionals (vitamins, minerals and supplements) product sectors.

The US pharmaceutical company, which remains confidential, has acquired an exclusive license for Tabwrap, one of the BioProgress Xgel dosage forms in a specific market sector and for the territory of North America and the European Union.
BioProgress will receive a payment of US$900,000 upon the first commercialisation and a royalty based on the licensee's sales price of all products which use the Tabwrap dosage form. The Tabwrap technology will initially be applied to a limited number of products which could be on sale before the end of 2005. Sales of the initial group of products, when fully introduced to the US market, are expected to generate royalty income for BioProgress of between $1m and US$1.5m per year. That amount could grow significantly as the Tabwrap technology is applied to higher volume products, new products and introduced into the European market in competition with old tablet coating technology.

The Tabwrap machines will be manufactured under license by the licensee and films for Tabwrap may be supplied to the licensee from the newly acquired BioProgress cGMP film facility in Tampa, Florida USA, generating further revenues and profits for the company.

To ensure that there is the security of multiple supply sources for film in North America, the US pharmaceutical company will also establish a pharmaceutical standard (cGMP) film manufacturing facility to supply their own film requirements under the exclusive license. This second facility will also exclusively supply BioProgress with film, giving BioProgress guaranteed additional cGMP film capacity in the USA as film requirements grow for all BioProgress technologies and customers in the North American market.

BioProgress CEO Graham Hind, said: 'Tabwrap is a technology designed to replace traditional tablet coating techniques by providing a non-gelatin lower-cost, faster, more efficient process. We can also manipulate the dissolution rate of the Tabwrap coating film to increase the dissolution rate of the tablet and add value to products by making the tablet active available to the body faster and facilitating a "faster acting" claim. It also enables a two-colour tablet product presentation not possible with traditional tablet coating methods, offering further product differentiation and marketing advantages over current tablet coating processes. As the Tabwrap film is made from already approved materials and the tablet cores remain unchanged, the regulatory issues are minimal and the technology adoption time and product time to market is relatively short.

'According to IRI, an independent pharmaceutical market monitor, the OTC medicines market in the US is valued at $10.8bn per annum. The European market is also extremely substantial. If our licensee is successful in securing even a modest share of this marketplace through Tabwrap, it is not unrealistic to anticipate that within a few years the BioProgress royalty stream on Tabwrap alone will be very SIGNIFICANT.'

BioProgress Executes New Development Agreement with Global Pharmaceutical Company
ATLANTA, GA (December 19, 2002) - BioProgress Technology International, Inc. (OTC BB: BPRG) today announced it has entered into a Development Agreement with a division of a major pharmaceutical company for several products based on BioProgress' XGel Film technology. The undisclosed company is among the top ten pharmaceutical companies in a ranking of global pharmaceutical sales for 2001. Details regarding the specific products have not been released.

http://www.bioprogress.com/html/news/archive/19-12-02.html

Dated: 9th March 2004

Part of the GH interview

Graham: That relates to another of our technologies, and were in active discussions for that, and what I dont want to do is create a milestone here that I am going to be held accountable for. I would expect that that deal will be concluded in the next few weeks. Its at a stage where most of the major issues, I think, have been resolved but you have to be so careful here. I think people get impatient with us that they did over the last announcement why are they taking so long Where weve got to be extremely careful is when we license, we have a whole range of patents and clearly some overlap into each technology. How we describe this, we have core patents relate to a specific technology Nrobe, Tabletwrap or Septum for example. Then we have what we call the tool kit, which is a whole range, which transcend both. Now obviously these large Companies want to license everything, they want to have everything exclusively and weve got to be extremely careful that we dont inadvertently conclude an agreement which prevents us from licensing another technology because of course every Company dealing with us has their own major patent attorneys who crawl all over it, and its quite complex so its important we do a deal that ensures that it isnt going to interrupt any of our future plans and thats why it often takes a little longer than perhaps we would like because we have to argue this quite vigorously.

Patricia: So exclusivity up to a point?

Graham: Exclusivity to a point; exclusivity that the licensee to be able to have protection but also for us to be able to have the freedom to operate across the broad range of technologies we have. And that does take time, and is complex.


In relation to a Brokers Report:

Graham: .......what we do need is a brokers note and that will come out in the next few weeks, and I didnt really want a note going out until it gave the full picture, clearly there were a lot of exciting things that were about to happen, there was no point in reporting and analysing the Company when youre only looking at 50% of what its potential is. So now, I think, were in a situation where the markets probably need a clear picture of how, what is the revenues potential look like, how big are these
markets, and thats, rather than predict that now Id rather ask you to wait, maybe 2-3 week when well probably come out with a properly considered view.


I like this bit - 'Quote' I would expect that that deal will be concluded in the next few weeks. Its at a stage where most of the major issues, I think, have been resolved but you have to be so careful here.

So do we think we have turned the corner regarding the price being driven down, seems like lots of positive news to come, am still holding for the long term and I personally havent been driven to sell.....

It is sometimes better to travel than arrive.

That's far too obscure for some of the posters on this thread Dil.

Stick in there adie. Checkout what happened to the price when the rights issue was executed. Think we are going to get a similar pattern.

cheers GF.

Wanted to find out more about the timing of the next announcement from BPRG and in my naivety made a few calls. Was told that announcements would be "drip fed" as and when there was actual news and interestingly, told that in May, Spider Man (presumably Spider Man 2) would be released in the US with massive PR INCLUDING aquafilm produced spider man sweetie strips. Any views on the implications for BPRG?
GF?
Anna

by courtesy of Vigilante Man and the MW bb.

'Over the next 10 days or so I'm staring down the barrel of a gun on 3 of my T+ trades so decision time beckoning hence spoke to GH earlier today.
Firstly have to say what an immediately impressive bloke to speak to as he took the time out of his busy schedule to respond to my call without delay.
Without going verbatim I got the confirmation I required that between now and 31 March the broker note will be published preceded by another announcement, and I have a strong feeling this is likely to be next week.

He is acutely aware that the share price is being distorted by the stock being heavily shorted although this should resolve 'very soon'. He went out of his way to assure me that nothing had fundamentally changed since Bio stood at 1.50+ and seems so enthusiastic about the 'multi technologies' yet to come.

Hope this helps anyone hanging in by their fingernails!

Dil
I think the quote is

"To travel hopefully is a better thing than to arrive, and the true success is to labor". - Robert Louis Stevenson

He bought shares in BPRG too did he ?

Dil - I think he went for Stagecoach in the end.....

lol , good win for your boys last night ..... I can't even blame the ref , there were three !!

from adv..

I must have listened to the interview with gh 6 or 7 times now . each time i listen to it i pick up a little bit that i didnot catch before .my value on the company at presant would be around the 1.50 mark but the bit that keeps coming back is that GH does not want a brokers note published until the other 50 percent of the current information is out . that i believe now is the swallow deal which must have a value of around 160-220 million this should push the value in my book up to 2.20-3.00 weather the share price actually gets there is of course anyones guess , but as we only have a matter of x trading days before that news is out it is worth the wait .

OT

Dil - pleased to have laid the bogey. We always do badly at Cardiff, probably because our fans have been chased away....! I saw the highlights on Meridian TV. Looked a ding-dong affair and a bit of a farce with the refs as you say. Now the big game on Saturday - home to Sunderland who are just behind us!!

A home win followed by a blockbuster deal for BPRG will do nicely :)

Letter to Shareholders



BioProgress plc

('BioProgress' or 'the Company')

Letter to Shareholders


BioProgress plc today issued its 2003 Report and Accounts and enclosed also a
letter to its Shareholders, the text of which follows.

'Please find enclosed your Company's annual report for the period ended 31st
December 2003. Some of the highlights have been captured on the CD-ROM which
comes with (but does not form part of) the accounts. I hope you enjoy watching
it.

'This is our maiden set of published accounts since our highly successful
listing on the LSE AIM market. Mentioned in the report are two significant post
2003 events. The first was the signing of the global licensing agreement for
our NROBE(R) technology with the FMC BioPolymer which we expect to be worth a
minimum of US$160 million to BioProgress in revenues during the first six years
and which runs for a total of nineteen years to 2023.

'The second event was the signing of the agreement with the un-named US
pharmaceutical company to license exclusively our TABWRAP(R) technology in a
particular market sector. I would like to take this opportunity to give
Shareholders a better understanding of the importance to the Company of this
licensing agreement, as some Shareholders may consider that an initial payment
of US$900,000 and anticipated royalty revenues of only US$1 to 1.5 million in
2005 may seem small by comparison with the revenues previously indicated for the
FMC licensing agreement.

'One of the key issues to bear in mind is the significance of my statement in
the announcement of the TABWRAP(R) agreement that the TABWRAP(R) licensee was
influential in the industry and that the US annual OTC medicines and vitamin
mineral supplement market according to independent monitors was valued at
US$10.8 billion. Figures for the full year 2003 show it has grown to US$11.1
billion.

'Our US TABWRAP(R) licensee is influential because according to IRI, an
independent research monitor, it currently has in excess of 13% of total sales
by value of the US $11.1 billion annual market across a broad range of product
categories. The BioProgress TABWRAP(R) royalties are based on a percentage of
the licensee's gross product sales and, as there are only modest administrative
costs attached, these royalties are almost entirely profit for BioProgress.

'The forecast of US$1 to 1.5 million royalties by 2005 represents an adoption of
the TABWRAP(R) technology by the licensee initially in around 5% of its current
product portfolio. We expect the licensee to progressively adopt TABWRAP(R)
across a number of its products and to use it for several new products. As a
result of this I expect the BioProgress royalty stream from this agreement to
grow significantly in the next five years.'


- Ends -

What fabulous news - just had to copy this from another B&B site:-

"Let me rub my eyes!

They have an OTC contract with a top ten pharma that accounts for 13% of a $11.1 Billion market.

or $1.443 Billion

so if 5% of the pharma production = $1.5 million per year

100% = $30 million per year PLUS new products so taking a 20 year view as with FMC this equates to:

$600 million!

DONT FORGET THIS IS ONE, YES ONE CONTRACT.

Based on future earnings from just these 2 contracts: this alone equates to 5 a share. Another two or three of these and then a quite serious valuation of 10 onwards is not out of the question.

As an ex-stockbroker I recommend you hold your shares!

AND YES PLEASE COPY AND PASTE ANYTHING I HAVE TO SAY ON ANY BULLETIN BOARDS YOU WISH.

I suggest any doubters read this!

http://www.bioprogress.com/html/news/archive/18-03-04.html

Shorters jumping ship like scalded rats.

cheers GF.

GF , I don't believe this was ever "heavily shorted" as quoted elsewhere. The sellers were sellers and the buyers are buyers (half them are probably the ones who chucked them earlier), simple as that.

140-144p is still key area.